IRAY TECHNOLOGY(688301)

Search documents
奕瑞科技:奕瑞科技第二届监事会第二十次会议决议公告
2023-08-28 11:42
上海奕瑞光电子科技股份有限公司 第二届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码:688301 | 证券简称:奕瑞科技 公告编号:2023-049 | | --- | --- | | 转债代码:118025 | 转债简称:奕瑞转债 | 一、监事会会议召开情况 2023 年 8 月 28 日,上海奕瑞光电子科技股份有限公司(以下简称"公司") 以现场及通讯方式召开了第二届监事会第二十次会议(以下简称"本次会议"), 会议通知已于 2023 年 8 月 24 日以电子邮件形式发出。本次会议由监事会主席丰 华先生主持,会议应出席监事 3 人,实际出席并表决的监事 3 人。本次会议的召 开及表决程序符合《中华人民共和国公司法》、《公司章程》等相关法律法规的规 定。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn/) 披露的《奕瑞科技 2023 年半年度报告》及其摘要。 表决结果:同意票 3 票、反对票 0 票、弃权票 0 票。 1 2.审议通过《 ...
奕瑞科技:奕瑞科技独立董事关于对公司第二届董事会第二十一次会议相关议案的独立意见
2023-08-28 11:42
我们认为,公司 2023年半年度募集资金的存放和使用符合中国证券监督管理委员 会、上海证券交易所关于上市公司募集资金存放和使用的相关规定,不存在违规使用募 集资金的行为,不存在改变或变相改变募集资金投向和损害股东利益的情况,我们同意 公司《2023年半年度募集资金存放与实际使用情况的专项报告》。 二、关于增加2023年度日常性关联交易预计额度的议案 上海奕瑞光电子科技股份有限公司独立董事 关于对公司第二届董事会第二十一次会议相关议案的独立意见 根据《上海奕瑞光电子科技股份有限公司章程》、《上海奕瑞光电子科技股份有限 公司独立董事制度》等规定,我们作为上海奕瑞光电子科技股份有限公司(以下简称"公 司")的独立董事,基于独立判断的立场,对公司提交第二届董事会第二十一次会议审 议的相关事项发表独立意见如下: 一、关于公司《2023年半年度募集资金存放与实际使用情况的专项报告》的议案 我们认为:公司增加 2023年度日常性关联交易预计额度符合公司经营业务的发展 需要,交易价格公允,符合法律、法规的规定以及相关制度的要求,未损害公司及其他 非关联方的利益,不存在损害中小股东利益的情形,我们一致同意通过该议案。 (本页以 ...
奕瑞科技:奕瑞科技2023年半年度募集资金存放与实际使用情况的专项报告
2023-08-28 11:42
一、募集资金基本情况 (一)实际募集资金金额、资金到账情况 1、2020 年公司首次公开发行股票募集资金情况 经中国证券监督管理委员会出具的《关于同意上海奕瑞光电子科技股份有限 公司首次公开发行股票注册的批复》(证监许可[2020]1823 号)同意,公司首次 公开发行人民币普通股(A 股)1,820 万股,每股发行价格人民币 119.60 元,募 集资金总额为人民币 217,672.00 万元,扣除承销及保荐费用等与发行有关的费用 19,055.06 万元(不含增值税),实际募集资金净额为人民币 198,616.94 万元。以 上募集资金净额已全部到位,经立信会计师事务所(特殊普通合伙)审验并出具 《验资报告》(信会师报字[2020]第 ZA15507 号)予以确认。 1 2、2022 年公司向不特定对象发行可转换公司债券募集资金情况 | 证券代码:688301 | 证券简称:奕瑞科技 | 公告编号:2023-047 | | --- | --- | --- | | 转债代码:118025 | 转债简称:奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 ...
奕瑞科技(688301) - 2023 Q1 - 季度财报
2023-04-26 16:00
2023 年第一季度报告 单位:元 币种:人民币 证券代码:688301 证券简称:奕瑞科技 转债代码:118025 转债简称:奕瑞转债 上海奕瑞光电子科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存 在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 ...
奕瑞科技:奕瑞科技关于召开2022年度暨2023年第一季度业绩说明会的公告
2023-04-26 11:50
| 证券代码:688301 | 证券简称:奕瑞科技 公告编号:2023-039 | | --- | --- | | 转债代码:118025 | 转债简称:奕瑞转债 | 上海奕瑞光电子科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 投资者可于 2023 年 5 月 10 日(星期三)至 5 月 16 日(星期二)16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 (ir@iraygroup.com)进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海奕瑞光电子科技股份有限公司(以下简称"公司")分别于 2023 年 3 月 17 日、2023 年 4 月 27 日在上海证券交易所网站(www.sse.com.cn)披露了《2022 年年度报告》《2023 年第一季度报告》,为便于广大投资者更全面深入地了解公 司的经营成果、财务状 ...
奕瑞科技(688301) - 2022 Q4 - 年度财报
2023-03-16 16:00
Dividend and Share Capital - The company plans to distribute a cash dividend of 29.00 CNY per 10 shares, totaling approximately 210.81 million CNY, which represents 32.87% of the net profit attributable to shareholders [2]. - The company intends to increase its total share capital by 4 shares for every 10 shares held, resulting in an increase of approximately 29.08 million shares, raising the total share capital to approximately 101.77 million shares [2]. - The company has established a cash dividend policy that aligns with its articles of association and shareholder return plan for 2022-2024 [189]. Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion in 2022, representing a year-over-year growth of 25% [12]. - The operating revenue for 2022 was CNY 1,549,116,657.78, reflecting a growth of 30.47% year-on-year, driven by rapid sales growth in dental and industrial products [21]. - The net profit attributable to shareholders was CNY 641,300,445.36, up 32.49% from the previous year, while the net profit after deducting non-recurring gains and losses increased by 51.18% to CNY 516,793,469.55 [21]. - Basic earnings per share rose to CNY 8.84, a 32.53% increase year-on-year, supported by the growth in net profit [21]. - The net cash flow from operating activities was CNY 316,620,618.89, an increase of 27.66% compared to the previous year, attributed to higher sales receipts [21]. Research and Development - The company has invested RMB 200 million in R&D for new technologies, focusing on improving the efficiency of X-ray imaging systems [12]. - The company's R&D investment accounted for 15.41% of operating revenue, an increase of 3.14 percentage points from the previous year [20]. - Research and development expenses increased by 63.87% to RMB 239 million, driven by enhanced R&D team construction and investment [112]. - The company applied for 66 new intellectual property rights during the reporting period, including 37 invention patent applications, and has a total of 398 registered or authorized IP rights [75][76]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2023 [12]. - A strategic acquisition of a local competitor is anticipated to be finalized in Q3 2023, which is expected to increase the company's market share by 10% [12]. - The company aims to develop comprehensive solutions that integrate hardware, software, and applications to improve overall service offerings [37]. - The company plans to deepen cooperation with strategic clients and expand market share in medical and industrial sectors, enhancing global customer relationships [142]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm [2]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy [2]. - The company has established a comprehensive governance structure to ensure compliance with legal and regulatory standards [147]. - The company’s board of directors included independent members, ensuring compliance with governance standards [175]. Risks and Challenges - The company faces risks related to intellectual property protection and potential technology leaks, which could negatively impact its competitive edge and operational performance [92]. - There is a risk of falling behind in technology and product development if the company fails to respond to revolutionary new technologies in the market [93]. - The company relies on a concentrated supply chain for key raw materials, with over 20% sourced from overseas, which poses risks if suppliers fail to deliver [95]. - The company is at risk of slower market demand and potential inability to digest new production capacity, which could affect overall business performance [109]. Employee and Management - The total number of employees has exceeded 1,200, with over 400 in R&D, representing a year-on-year growth of 57% and 59% respectively, enhancing the company's talent pool [34]. - The company has implemented an employee stock incentive plan, granting shares to 263 employees to enhance motivation and retention [186]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 7.9187 million RMB [171]. - The company is focused on attracting and retaining high-quality talent to support its growth and innovation strategies [144]. Product Development and Innovation - New product development includes the launch of a next-generation Flat Panel Detector, expected to enhance imaging quality by 30% compared to previous models [11]. - The company has developed a high-performance readout chip for digital X-ray detectors, achieving commercial mass production and reaching international product performance levels [66]. - The company has completed the development of core components for CT detectors, including collimators, scintillators, and photodiodes, and is focused on achieving full integration of CT detectors [64]. - The company has developed several types of flat panel detectors and line array detectors to meet diverse market needs in the dental and industrial sectors [58]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting the success of recent service enhancements [159]. - The company is exploring partnerships with local firms to strengthen its supply chain and distribution networks [157]. - The company aims to enhance its customer engagement strategies, aiming for a 40% increase in customer retention rates [163]. Future Outlook - The company provided guidance for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion [159]. - Future trends in digital X-ray detectors include advancements towards lower radiation doses, real-time imaging, and 3D rendering capabilities [60]. - The company is actively investing in new product development and technological advancements to maintain competitive advantage [154].